A Real World Study of Paxlovid for the Treatment of Hospitalized Patients Confirmed With COVID-19

A Real World Study of Paxlovid for the Treatment of Hospitalized Patients Confirmed With COVID-19

The study was designed to analyze the efficacy and safety of Paxlovid for the treatment of COVID-19.

The study is a real-world study and the case records of patients with COVID-19 who visit Huashan Hospital affiliated to Fudan University from 2022 to 2027 and receive Paxlovid therapy will be collected in this study. The medical data including patient demographic, clinical characteristics, laboratory examination, history of treatments, adverse reactions and treatment outcome will be extracted to analyze the effectivity and safety of paxlovid and explore the prognosis-relevant factors of COVID-19.

Inclusion Criteria:

• Participants who have a positive SARS-CoV-2 test result;
• Participants who have one or more mild or moderate COVID-19 symptoms.

Exclusion Criteria:

• No specific exclusion criteria in this real world study.